Long-term Immunogenicity and Boostability of the 13-valent Pneumococcal Conjugate Vaccine Followed by the 23-valent Pneumococcal Polysaccharide Vaccine in Adults Receiving Immunosuppressive Therapy and Adults With HIV-3-year Follow-up of a Prospective Cohort Study.

ABSTRACT:

Background

The long-term immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) remains unclear among immunocompromised patients (ICPs).

Methods

This 3-year follow-up of a previously reported prospective cohort study included people with human immunodeficiency virus (HIV) (PWH), patients on immunosuppressive therapy, and immunocompetent controls who received PCV13 followed by PPSV23 2 months later. IgG levels for all 24 vaccine serotypes were measured 3 years after PCV13 (M36). The primary outcome was the seroprotection rate (SPR) at M36, defined as IgG concentrations ≥1.3 μg/mL for 17/24 vaccine serotypes. To assess immunological memory, we measured rapid recall responses 7 days after a P

SUBMITTER: Schnyder JL 

PROVIDER: S-EPMC12728288 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature